Promising new experimental combination therapy in Hypoxic Ischemic Injury

In a study published in Neonatology on Oct. 13, 2017, researchers from George Washington University, Washington, DC using newborn piglet models exposed to hypoxia-ischemia studied the ffect of standard cooling therapy (therapeutic hypothermia) alone and in combination with a selective Src kinase inhibitor, PP2, that blocks a regulatory enzyme of apoptosis (cell death). PP2 is a substance that has frequently been used in cancer research as a "selective" inhibitor for Src-family kinases. This stud...
Continue reading

ICNA 2018 Awards Announced

  The International Child Neurology Association is pleased to announce the names of those selected to receive the ICNA 2018 Awards at the 15th International Child Neurology Congress to be held in Mumbai, India November 15-18, 2018. Helen Cross, United Kingdom   Frank Ford Award 2018 Professor Helen Cross is The Prince of Wales's Chair of Childhood Epilepsy and Honorary Consultant in Paediatric Neurology at UCL Institute of Child Health, Great Ormond Street Hospital for Children NHS Tru...
Continue reading

Dietary supplement Glucosamine may have a role in reducing excitability in brain cells

In an article published in the Journal of Neuroscience Prof. John Chatham, of the Department of Pathology at the University of Alabama at Birmingham, and colleagues report that increasing O-GlcNAcylation levels in brain cells using the dietary supplement "glucosamine" widely used as a supplement to help reduce pain in osteoarthritis and other conditions was found to reduce  reduce neural excitability in rodents. The researchers had in a previous study shown that increases in prote...
Continue reading

Circadian Rhythm Protein CLOCK linked to severe epilepsy

In new research published in Neuron this week researchers from Brown University in Providence, RI suggests that disruption of  the circadian rhythm protein CLOCK alters cortical circuits and may lead to generation of focal epilepsy.  Dr. Liu and her colleagues used resected brain tissue from epilepsy surgery for focal cortical dyplasias and analysed the  tissue's transcriptome, or a survey of the messenger RNA (mRNA) in any given population of cells. They ...
Continue reading

Ataluren shows promise for muscular dystrophy in phase 3 clinical trial


In a paper just published online in the journal The Lancet , Craig McDonald and colleagues at 53 study sites in 18 countries describe the clinical benefit of using the drug ataluren for a certain group of patients carrying a specific "nonsense mutation" for Duchenne muscular dystrophy. Duchenne muscular dystrophy (DMD) is a progressive and life-limiting X-linked recessive disorder caused by mutations in the DMD gene that result in reduced or absent dystrophin production. Dystrophin is part of th...
Continue reading